Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus

NCT02229929 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

89

Enrollment

INDUSTRY

Sponsor class

Conditions

Pruritus
Uremic Pruritus

Interventions

DRUG: Part A: Placebo
DRUG: Part A: CR845 0.5 mcg/kg
DRUG: Part A: CR845 1.0 mcg/kg
DRUG: Part A: CR845 2.5 mcg/kg
DRUG: Part B: Placebo
DRUG: Part B: CR845 1.0 mcg/kg

Sponsor

Cara Therapeutics, Inc.